Upsher-Smith has announced the US launch of Tosymra sumatriptan nasal spray. The FDA approved Tosymra for the treatment of migraine with or without aura in January 2019, and Upsher-Smith acquired US rights to the nasal spray from Promius Pharma in June 2019.
The Tosymra formulation uses Intravail transmucosal absorption enhancement technology and is delivered via Aptar Pharma’s Unidose Liquid System device.
Upsher-Smith President and CEO Rusty Field commented, “We’re excited to launch Tosymra, the third product in Upsher-Smith’s growing migraine portfolio, which includes Qudexy XR and Zembrace SymTouch. Many patients face challenges during migraine attacks that make available acute treatment options inadequate. Tosymra nasal spray offers an alternative for patients whose symptoms interfere with taking oral medication or who may be dissatisfied with their current treatment regimen.”
Aptar Pharma President Gael Touya said, “We are pleased that Aptar Pharma’s Unidose System has once again been approved by the FDA and launched with an important new nasal treatment for acute treatment of migraine that provides a patient-friendly delivery approach. Our lab and analytic service capabilities combined with our unique drug delivery devices create tremendous value for our customers and help them secure approval. The ultimate end result is that we help expand access to treatments with our life-improving, patient-friendly systems, something for which we are very proud.”
Read the Upsher-Smith press release.
Read the Aptar Pharma press release.
